Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

How Often Should Cannabis Be Used to Stabilise Behaviour in Dementia? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

According to current NICE and NHS guidance, there is no approved frequency or dosing schedule for using cannabis to stabilise behaviour in dementia. From 2023 to 2025, evidence has shown that cannabis, particularly THC-containing products, carries uncertain efficacy and notable risks for older adults with cognitive impairment (NHS; NICE NG144; Alzheimer’s Society). 

Can medical cannabis be accessed legally for women’s health?

What NHS And NICE Say 

NICE and NHS guidance limit cannabis-based medicinal products to specific conditions: severe epilepsy, chemotherapy-induced nausea, and multiple sclerosis-related spasticity. Dementia is not included in these categories, meaning there are no recognised protocols or frequency guidelines for cannabis use in behavioural symptoms. Any use for dementia would be off-label and must occur under specialist supervision only (NHS England). 

What Research Says About Frequency and Effects 

Recent peer-reviewed studies highlight that no safe or effective frequency has been established for cannabis use in dementia. Evidence from 2024–2025 suggests that even intermittent THC exposure can impair short-term memory, attention, and decision-making in older adults (PubMed 2024).  

Trials investigating oral CBD or mixed THC/CBD capsules for agitation have used strictly monitored, low-dose regimens and not inhaled or self-administered cannabis. Results remain inconclusive, with researchers warning against routine or repeated use. Experts from Alzheimer’s Society UK confirm that there is no clinical proof cannabis can stabilise behaviour, and frequent use may increase confusion or agitation. 

Safety And Behavioural Considerations 

Frequent cannabis use may trigger hallucinations, drowsiness, and worsening disorientation, particularly in those older adults who are on sedatives or anticholinergic medication (NICE NG144). Respiratory irritation is also a concern for inhaled products such as vaping. NICE and NHS England advise clinicians to prioritise evidence-based therapies like behavioural interventions or licensed medications before considering cannabis products. 

Clinical Bottom Line 

  • No NICE or NHS guideline supports cannabis use to stabilise behaviour in dementia 
  • There is no evidence-based frequency or dosing recommendation for dementia care 
  • Frequent use may worsen confusion, agitation, or sedation 
  • Oral formulations are under study but remain experimental and unlicensed for dementia 
  • Behavioural and environmental interventions remain first-line approaches 

AlleviMed: Understanding Medical Cannabis Regulations 

AlleviMed provides clear, educational resources on how medical cannabis is prescribed legally within the UK. Its materials help patients and families understand eligibility, risks, and the boundaries of current regulations, especially regarding conditions like dementia where evidence is lacking. AlleviMed does not prescribe or promote cannabis but focuses on explaining the UK framework for safe and regulated access. For more information, visit AlleviMed. 

Takeaway 

Cannabis should not be used regularly or routinely to stabilise behaviour in dementia. There is no safe frequency, no approved protocol, and no proven benefit according to NHS, NICE, or Alzheimer’s Society UK. Frequent use can increase confusion, sedation, and other adverse effects, particularly in vulnerable older adults. Families and carers should always seek medical guidance from dementia specialists before considering any unlicensed treatment.  

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories